MBRX - Moleculin engages IQVIA to manage potential COVID-19 clinical trial

Moleculin Biotech (MBRX) announces the engagement of contract research organization IQVIA Biotech to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.WP1122 is a prodrug of 2-DG, a well-known antimetabolite with the ability to inhibit glycolysis and alter glycosylation, two processes critical to coronaviruses like SARS-CoV-2, the virus responsible for COVID-19.The companies did not provide further details on the collaboration.Shares up more than 4% premarket.

For further details see:

Moleculin engages IQVIA to manage potential COVID-19 clinical trial